| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia.
|
Blood
|
2011
|
2.08
|
|
2
|
Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides.
|
Blood
|
2004
|
1.81
|
|
3
|
Mastocytosis: pathology, genetics, and current options for therapy.
|
Leuk Lymphoma
|
2005
|
1.61
|
|
4
|
PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects.
|
Blood
|
2005
|
1.53
|
|
5
|
Immunohistochemical detection of vascular endothelial growth factor (VEGF) in the bone marrow in patients with myelodysplastic syndromes: correlation between VEGF expression and the FAB category.
|
Leuk Lymphoma
|
2006
|
1.42
|
|
6
|
A kinase-independent function of CDK6 links the cell cycle to tumor angiogenesis.
|
Cancer Cell
|
2013
|
1.37
|
|
7
|
Low-level expression of proapoptotic Bcl-2-interacting mediator in leukemic cells in patients with chronic myeloid leukemia: role of BCR/ABL, characterization of underlying signaling pathways, and reexpression by novel pharmacologic compounds.
|
Cancer Res
|
2005
|
1.16
|
|
8
|
Pathogenesis and classification of eosinophil disorders: a review of recent developments in the field.
|
Expert Rev Hematol
|
2012
|
1.15
|
|
9
|
Polo-like kinase 1 (Plk1) as a novel drug target in chronic myeloid leukemia: overriding imatinib resistance with the Plk1 inhibitor BI 2536.
|
Cancer Res
|
2010
|
1.10
|
|
10
|
CD25 indicates the neoplastic phenotype of mast cells: a novel immunohistochemical marker for the diagnosis of systemic mastocytosis (SM) in routinely processed bone marrow biopsy specimens.
|
Am J Surg Pathol
|
2004
|
1.06
|
|
11
|
Expression of activated STAT5 in neoplastic mast cells in systemic mastocytosis: subcellular distribution and role of the transforming oncoprotein KIT D816V.
|
Am J Pathol
|
2009
|
1.06
|
|
12
|
Identification of proapoptotic Bim as a tumor suppressor in neoplastic mast cells: role of KIT D816V and effects of various targeted drugs.
|
Blood
|
2009
|
1.04
|
|
13
|
Cardiac glycosides induce cell death in human cells by inhibiting general protein synthesis.
|
PLoS One
|
2009
|
1.00
|
|
14
|
Transcriptome analysis of human cancer reveals a functional role of heme oxygenase-1 in tumor cell adhesion.
|
Mol Cancer
|
2010
|
0.96
|
|
15
|
Identification of MCL1 as a novel target in neoplastic mast cells in systemic mastocytosis: inhibition of mast cell survival by MCL1 antisense oligonucleotides and synergism with PKC412.
|
Blood
|
2007
|
0.96
|
|
16
|
KIT-D816V-independent oncogenic signaling in neoplastic cells in systemic mastocytosis: role of Lyn and Btk activation and disruption by dasatinib and bosutinib.
|
Blood
|
2011
|
0.94
|
|
17
|
Synergistic antiproliferative effects of KIT tyrosine kinase inhibitors on neoplastic canine mast cells.
|
Exp Hematol
|
2007
|
0.92
|
|
18
|
Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KIT.
|
Haematologica
|
2007
|
0.91
|
|
19
|
Immunohistochemical detection of VEGF in the bone marrow of patients with acute myeloid leukemia. Correlation between VEGF expression and the FAB category.
|
Am J Clin Pathol
|
2003
|
0.90
|
|
20
|
Immunohistochemical detection of VEGF in the bone marrow of patients with chronic myeloid leukemia and correlation with the phase of disease.
|
Am J Clin Pathol
|
2004
|
0.89
|
|
21
|
Identification of oncostatin M as a STAT5-dependent mediator of bone marrow remodeling in KIT D816V-positive systemic mastocytosis.
|
Am J Pathol
|
2011
|
0.87
|
|
22
|
Myeloid leukemias express a broad spectrum of VEGF receptors including neuropilin-1 (NRP-1) and NRP-2.
|
Leuk Lymphoma
|
2007
|
0.87
|
|
23
|
Detection of vascular endothelial growth factor (VEGF) and VEGF receptors Flt-1 and KDR in canine mastocytoma cells.
|
Vet Immunol Immunopathol
|
2006
|
0.86
|
|
24
|
The PI3-kinase/mTOR-targeting drug NVP-BEZ235 inhibits growth and IgE-dependent activation of human mast cells and basophils.
|
PLoS One
|
2012
|
0.85
|
|
25
|
Identification of oncostatin M as a JAK2 V617F-dependent amplifier of cytokine production and bone marrow remodeling in myeloproliferative neoplasms.
|
FASEB J
|
2011
|
0.84
|
|
26
|
Identification of heat shock protein 32 (Hsp32) as a novel survival factor and therapeutic target in neoplastic mast cells.
|
Blood
|
2007
|
0.83
|
|
27
|
Identification of basophils as a major source of hepatocyte growth factor in chronic myeloid leukemia: a novel mechanism of BCR-ABL1-independent disease progression.
|
Neoplasia
|
2012
|
0.83
|
|
28
|
The pan-Bcl-2 blocker obatoclax promotes the expression of Puma, Noxa, and Bim mRNA and induces apoptosis in neoplastic mast cells.
|
J Leukoc Biol
|
2013
|
0.83
|
|
29
|
The CML-related oncoprotein BCR/ABL induces expression of histidine decarboxylase (HDC) and the synthesis of histamine in leukemic cells.
|
Blood
|
2006
|
0.81
|
|
30
|
Evaluation of in vivo antineoplastic effects of rapamycin in patients with chemotherapy-refractory AML.
|
Eur J Intern Med
|
2009
|
0.80
|
|
31
|
Chronic myeloid leukemia: pathophysiology, diagnostic parameters, and current treatment concepts.
|
Wien Klin Wochenschr
|
2003
|
0.79
|
|
32
|
Eosinophilia in systemic mastocytosis: clinical and molecular correlates and prognostic significance.
|
J Allergy Clin Immunol
|
2007
|
0.79
|
|
33
|
Targeting of heat-shock protein 32/heme oxygenase-1 in canine mastocytoma cells is associated with reduced growth and induction of apoptosis.
|
Exp Hematol
|
2008
|
0.77
|
|
34
|
Immunohistochemical detection of histidine decarboxylase in neoplastic mast cells in patients with systemic mastocytosis.
|
Hum Pathol
|
2006
|
0.76
|
|
35
|
Transfusion-related exposure to the plasticizer di(2-ethylhexyl)phthalate in patients receiving plateletpheresis concentrates.
|
Transfusion
|
2005
|
0.75
|
|
36
|
A Kinase-Independent Function of CDK6 Links the Cell Cycle to Tumor Angiogenesis.
|
Cancer Cell
|
2016
|
0.75
|
|
37
|
Evaluation of normal and neoplastic human mast cells for expression of CD172a (SIRPalpha), CD47, and SHP-1.
|
J Leukoc Biol
|
2005
|
0.75
|